InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Biotechnology and patentability: navigating unchartered waters in Australia and the US


The debate over the patentability of isolated DNA has raged around the world. Tania Obranovich compares the two Myriad decisions from the highest courts in Australia and the US and explains how the Australian decision has called into question what had long been thought of as a fundamental pillar of Australian patent law

Myriad's BRCA patents, which claim both breast cancer diagnostic methods and the isolated BRCA DNA molecules, have courted significant controversy both in Australia and the US in recent years. Extensive judicial consideration in relation to the patent eligibility of isolated...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

RT @mdloney: SCOTUS TC Heartland v Kraft Foods Group Brands oral argument transcript is up! https://t.co/v29vEKCILp

Mar 27 2017 07:50 ·  reply ·  retweet ·  favourite
ManagingIP profile

Likely to be an important question for some applicants, with UPC due to come into force in December this year https://t.co/ASuSYUpRqd

Mar 27 2017 04:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Don't forget to sign up for our next webinar, on IP in Asia, this Thursday at 3pm (London) https://t.co/gh3Ka8t9q1 @inoviaIP @Minesoftnews

Mar 27 2017 04:38 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements